Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
Kallesh D. Jayappa(Carter Center), Michael J. Weber(Carter Center), Timothy P. Bender(Carter Center), L. Kyle Brett, Stefan Bekiranov, Vicki L. Gordon, Rosa I. Gallagher(George Mason University), Mark J. Axelrod(University of Virginia), Brian J. Capaldo(University of Virginia), Michael E. Williams(University of Virginia), Craig A. Portell(University of Virginia), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Julia Wulfkuhle(University of California, San Francisco)
Cited by 116
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and Akt
|Molecular and Cellular Biology|1997|1.1k
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
|Blood|2015|408
Androgen Receptor Phosphorylation
|Journal of Biological Chemistry|2002|353